Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey Jay Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016
Cited by 1,403 works. doi:10.1016/s1470-2045(16)30498-3
Authors
- Corey Jay Langer
- Shirish M. Gadgeel
- Hossein Borghaei
- Vassiliki A. Papadimitrakopoulou
- Amita Patnaik
- Steven Francis Powell
- Ryan D. Gentzler
- Renato G Martins
- James P. Stevenson
- Shadia Ibrahim Jalal
- Amit W. Panwalkar
- James Chih‐Hsin Yang
- Matthew A. Gubens
- Lecia Van Dam Sequist
- Mark Magdi Awad
- Joseph Fiore
- Yang Ge
- Harry Raftopoulos
- Leena Gandhi
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- On Closed Testing Procedures with Special Reference to Ordered Analysis of Variance
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer